Highlights Kane Biotech Inc.

Equities

KNE

CA4838092084

Market Closed - Toronto S.E. Other stock markets 03:56:58 2024-07-08 pm EDT			5-day change	1st Jan Change
0.15 ^CAD	+3.45%		0.00%	+87.50%

Jun. 27	Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel	MT
Jun. 27	Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel to ProgenaCare Global	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel	Jun. 27	MT
Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel to ProgenaCare Global	Jun. 27	MT
Kane Biotech Brief: Says Made First Commercial Sale of revyve Antimicrobial Wound Gel to ProgenaCare Global	Jun. 27	MT
Kane Biotech Makes First Commercial Sale of revyve? Antimicrobial Wound Gel to ProgenaCare Global	Jun. 27	CI
Kane Biotech Signs License Agreement with I-MED Pharma	Jun. 25	MT
Kane Biotech Signs Worldwide License Agreement with I-MED Pharma Inc	Jun. 25	CI
Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	May. 23	MT
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	May. 15	MT
Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	Apr. 15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11	MT
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	Mar. 26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20	MT
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	Nov. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kane Biotech Inc.

Equities

KNE

CA4838092084

Highlights

Filters